BioNTech (NASDAQ:BNTX) had its target price increased by SVB Leerink from $110.00 to $118.00 in a report released on Monday morning, Benzinga reports. SVB Leerink currently has a market perform rating on the stock.
BNTX has been the topic of a number of other reports. Zacks Investment Research raised BioNTech from a sell rating to a hold rating in a report on Tuesday, March 30th. Berenberg Bank set a $130.00 price objective on BioNTech and gave the company a buy rating in a research report on Tuesday, April 6th. Finally, JPMorgan Chase & Co. set a $104.00 price objective on BioNTech and gave the company a neutral rating in a research report on Tuesday, April 6th. Five research analysts have rated the stock with a hold rating and three have assigned a buy rating to the company’s stock. BioNTech currently has a consensus rating of Hold and an average price target of $102.89.
Shares of BioNTech stock opened at $168.95 on Monday. BioNTech has a 52 week low of $43.00 and a 52 week high of $176.00. The stock has a 50 day moving average price of $112.98 and a two-hundred day moving average price of $105.67. The stock has a market capitalization of $40.80 billion, a PE ratio of -84.48 and a beta of -1.74.
Several hedge funds and other institutional investors have recently made changes to their positions in the stock. John W. Brooker & Co. CPAs acquired a new position in BioNTech during the first quarter worth about $33,000. Captrust Financial Advisors grew its holdings in BioNTech by 433.3% in the fourth quarter. Captrust Financial Advisors now owns 400 shares of the company’s stock valued at $33,000 after purchasing an additional 325 shares during the period. US Bancorp DE purchased a new stake in BioNTech in the fourth quarter valued at approximately $46,000. Stonehage Fleming Financial Services Holdings Ltd purchased a new stake in BioNTech in the fourth quarter valued at approximately $49,000. Finally, Park Capital Group purchased a new stake in BioNTech in the fourth quarter valued at approximately $50,000. Hedge funds and other institutional investors own 10.75% of the company’s stock.
BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is involved in the developing of FixVac product candidates, including BNT111, which is in Phase I clinical trial for advance melanoma; BNT112 that is in Phase I/IIa trial for prostate cancer; BNT113, which is in Phase I/II trial to treat HPV+ head and neck cancers; BNT114 that is in Phase I clinical trial for triple negative breast cancer; BNT115 in a Phase I trial in ovarian cancer; and BNT116 for non-small cell lung cancer.It also develops neoantigen specific immunotherapies, such as Autogene cevumeran (BNT122), which is in Phase II clinical trial for first-line melanoma, as well as in Phase I clinical trial to treat multiple solid tumors; mRNA intratumoral immunotherapy comprising SAR441000 that is in Phase I clinical trial for solid tumors; and BNT141 and BNT142 to treat multiple solid tumors.
Receive News & Ratings for BioNTech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioNTech and related companies with MarketBeat.com's FREE daily email newsletter.